Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06689839

Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a standard of care control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)

Recruiting

Interested in participating?

Request Info

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St Andrews War Memorial Hospital, Spring Hill, Queensland, Australia

Loading trial locations.

About this study

The study is designed to demonstrate that the F2 Cerebral Protection System (CPS) performs in a consistent manner as the control group in terms of safety, and the F2 Cerebral Protection System (CPS) will be superior in performance when compared to the control group in terms of effectiveness in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Age ≥ 50 years.
  • Patient meets the established criteria and indications for commercially available TAVR via transfemoral access and is scheduled to undergo TAVR per their treating physician.
  • Patient is willing and able to comply with protocol-specified follow-up evaluations.
  • Patient is able and willing to provide written informed consent.
  • Patient meets all criteria for use of control device (Sentinel device, per IFU).

Key Exclusion Criteria:

General Exclusion Criteria:

  • Patient requires an urgent or emergent TAVR procedure.
  • Any interventional cardiovascular procedure performed within 30 days prior to TAVR procedure or planned within 30 days post-TAVR procedure.
  • Diagnostic cardiac catheterization within 10 days prior to TAVR procedure.
  • Evidence of an acute myocardial infarction within 3 months prior to TAVR procedure.
  • Prior prosthetic heart valve in any position.
  • Known intracardiac thrombus.
  • Active infection or endocarditis.
  • Patient is contraindicated for anti-platelet and/or anticoagulant therapy.
  • Patient refuses blood transfusion.
  • Renal insufficiency (creatinine > 2.5 mg/dL or GFR < 30) and/or renal replacement therapy at the time of screening.
  • Patients with hepatic failure (Child-Pugh class C).
  • Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 30%.
  • Females who are pregnant or nursing or plan to become pregnant during their participation in the study.

Neurological Exclusion Criteria:

  • Modified Rankin Scale (mRS) ≥ 2 at screening.
  • Cerebrovascular event including TIA within 6 months of the procedure.
  • Patient has active major psychiatric disease, known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation.
  • Patient has severe visual, auditory, or learning impairment.
  • Patient has neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.

Magnetic Resonance Imaging Exclusion Criteria:

  • Contraindications to MRI (participants with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).
  • High risk of complete AV block after TAVR, with the need of permanent pacemaker.
  • Claustrophobia precluding MRI scanning.

Anatomical and CT Exclusion Criteria:

  • Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath, vascular access or filter deployment.
  • Presence of cardiovascular implant in aorta and/or peripheral access vessels.
  • Access vessels with excessive tortuosity.
  • Aortic arch, which is heavily calcified, severely atheromatous, or severely tortuous.

Treatment and study plan

F2 Filter and Delivery System

Device

Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure

transcatheter aortic valve replacement (TAVR)

Procedure

Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device

Primary outcomes

  1. Major Adverse Cardiac and Cerebrovascular Events (MACCE)

    Time frame: 30 days post procedure

    MACCE includes the composite of death, all stroke, acute kidney injury (AKI) stage 3 or 4 within 7 days post-index procedure Valve Academic Research Consortium 3 (VARC-3) and any major vascular complication (VARC-3)

  2. Total New Lesion Volume

    Time frame: 8-72 hours post procedure

    Total new lesion volume (TNLV) in the brain assessed by diffusion weighted magnetic resonance images (DW-MRI)

Secondary outcomes

  1. Stroke

    Time frame: 30 days post procedure

    Incidence of all stroke events

Other outcomes

  1. Performance

    Time frame: During procedure

    Technical success (% of patients with successful device deployment, position and retrieval) and procedure success (% of patients with technical device success and no device-related safety events)

  2. Mortality & Stroke Rates

    Time frame: 30 days post procedure

    Incidences of all-cause mortality, major stroke, minor stroke events

  3. Freedom from Lesions

    Time frame: 8-72 hours post procedure

    Measure presence or absence of new lesions in the brain, assessed by diffusion weighted magnetic resonance images (DW-MRI)

  4. Average Lesion Size

    Time frame: 8-72 hours post procedure

    Measure average lesion size in the brain, assessed by diffusion weighted magnetic resonance images (DW-MRI)

  5. Neurological Outcomes-National Institute of Health Stroke Scale (NIHSS)

    Time frame: 30 days post procedure

    Use National Institute of Health Stroke Scale (NIHSS) to measure stroke severity on a scale of 0-41 (low score is better outcome).

  6. Neurological Outcomes-Montreal Cognitive Assessment (MoCA)

    Time frame: 30 days post procedure

    Use Montreal Cognitive Assessment (MoCA) to measure cognitive impairment on a scale of 0-30 (high score is better outcome).

  7. Neurological Outcomes-Modified Rankin Scale (MRS)

    Time frame: 30 days post procedure

    Use Modified Rankin Scale (MRS) to measure neurological disability on scale of 0-6 (Low score is better outcome)

  8. Major Vascular Complication & Bleeding

    Time frame: During procedure

    Measure major vascular complications (as defined by VARC-3) & major bleeding (Type 3, Type 4 as defined by VARC- 3)

  9. Hospital Readmissions

    Time frame: 30 days post procedure

    Measure number of hospital readmissions at 30 days and number of ICU readmissions during hospital stay and 30 days

  10. Index Hospital Length of Stay (LOS)

    Time frame: Through 30 days

    Measure Index hospitalization LOS

  11. Index Hospitalization ICU Length of Stay (LOS)

    Time frame: Through 30 days

    Measure Index hospitalization ICU length of stay

  12. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: 30 days post procedure

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-reported questionnaire that measures physical function, symptoms, social function, and quality of life, on a scale from 0 to 100 (higher score is better outcome).

  13. Short Form (SF-12) Questionnaire

    Time frame: 30 days post procedure

    The Short Form (SF-12) Questionnaire is a self-reported questionnaire that assess the impact of health on an individual's everyday life, on a scale from 0 to 100 (higher score is better health).

Study contacts

Contact information is provided by the study sponsor or research team.

Kathleen S Calderon

CONTACT

[email protected]

3072502726

Sponsors and collaborators

Lead sponsor

EnCompass Technologies, Inc.

Industry

Collaborators

  • Avania
  • Insight Medical Consulting

Registry information

Official study title

A Prospective, Randomized, Multicenter, Single-blind Trial to Assess the Safety and Effectiveness of the Encompass F2 Cerebral Protection System Vs. Standard of Care (Unprotected or Sentinel® Cerebral Protection System) During Transfemoral Transcatheter Aortic Valve Replacement

Acronym: SHIELD

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Nov 15, 2024
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.